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Weconclude that theTHLE-CYPcellmodel enables in vitro inves-
tigation of both CYP independent and CYP mediated processes
which may contribute to DILI, and also exploration of underly-
ing mechanisms (e.g. bioactivation of clozapine by 2D6). If used
in drug discovery, this approach has the potential to aid in rational
design and selection of compounds with reduced DILI liability, and
could enable early deselection of drug candidates with signiﬁcant
potential to cause DILI in man.
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It has been proposed, that inhibition of hepatobiliary trans-
porters may play an important role in the development of
drug-induced liver injury (DILI) (Wagner, 2009; Stieger, 2007). To
provide further understanding of the relationship between inhi-
bition of the canalicular transporter bile salt efﬂux pump (Bsep;
Abcb11) andDILI inman,we have assessed inhibition of Bsep activ-
ity in vitro by hepatotoxic and non-hepatotoxic marketed drugs.
Inhibition of rat Bsep was analysed in inverted plasma mem-
brane vesicles prepared from transfected Sf21 insect cells. We
quantiﬁed the adenosine triphosphate (ATP)-dependent uptake of
the probe substrate [3H]-taurocholate by a rapid ﬁltration tech-
nique (Stieger et al., 2000). In addition, inhibition of Bsep function
in sandwich-cultured primary rat hepatocytes was assessed using
cholyllysylﬂuorescein (CLF) as aprobe substrate, byquantifyingCLF
efﬂux into canalicular pockets using high content imaging and a
Cellomics ArrayscanTM algorithm (manuscript in preparation).
Potent inhibition of rat Bsep activity in vesicles (IC50 <300M)
was observed with 22/42 drugs (52%) associated with cholestatic
or mixed liver injury in man, 6/25 drugs (32%) associated with
hepatocellular liver injury and 5/23 non-hepatotoxic drugs (17%)
(Fig. 1A).
A high correlation between potency of rat Bsep inhibition in
vesicles and hepatocytes was observed (r2 = 0.79). However, the
apparent potency of inhibition was greater in hepatocytes than in
vesicles for many of the tested drugs (Fig. 1B). The compounds that
exhibited potent inhibition of Bsep in both experimental systems
included the withdrawn drugs troglitazone and nefazodone, and
bosentan and ketoconazole, both of which have a DILI black box
warning.
We conclude that potent Bsep inhibition by drugs correlates
with increased risk of cholestatic drug hepatotoxicity in man, and
that in vitro evaluation of this liability is useful for DILI hazard
identiﬁcation.
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Mortality rates are on the increase from liver disease in the
developed world, particularly in Scotland. The liver has an enor-
mous capacity for wound repair and regeneration after injury, but
early diagnosis is essential. Despite the high number of deaths each
year from liver disease, hepatologists still lack relevant diagnostic
biomarkers to detect early liver disease.
The aim of this project is to identify a suitable biomarker
to detect early liver disease. Insulin-like growth factor binding
protein-5 (IGFBP-5) is one such potential biomarker. IGFBP-5 has
already been shown to be upregulated in skin ﬁbrosis (Yasuoka
et al., 2006a), ﬁbrosis of the lung (Yasouka et al., 2006b) and has
been identiﬁed as a genetic marker for intrahepatic cholangiocar-
cinoma (Blechacz and Gores, 2008). Its role in liver damage is being
investigated using an in vitromodel of chronic low level toxic insult
in primary cultures of rat hepatocytes (male Sprague–Dawley rats,
180–220g).
The effects of lowconcentrations of twooxidative toxins (Mena-
dione (0.1, 1, 5 and 10M) and hydrogen peroxide (0.01, 0.05,
Fig. 1. Inhibition of rat Bsep activity by DILI compounds in vesicles (A) and correlation of IC50 values between vesicles and hepatocytes (B).
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Fig. 1. IGFBP-5 release from primary rat hepatocytes exposed to Menadione and hydrogen peroxide was measured using media samples collected over 0–3 days, 3–6 days
and 6–9 days (results are mean± SEM, n=3, *P<0.05, by one-way ANOVA followed by Dunnett’s multiple comparison test).
0.1 and 0.5mM)) were assessed over a period of 9 days in cul-
ture. Fresh toxin was added daily and the Williams’ E medium
changedevery threedays. Toxicity via oxidative stresswas assessed
by measuring reduced glutathione (GSH) content and WST-1 assay
(Roche Applied Science, cat. no. 11 644 807 001). The cell num-
ber was assessed using crystal violet (CV) staining and IGFBP-5
secretion into the medium was measured using a sandwich ELISA
assay.
Oxidative stress was observed and both toxins caused a sig-
niﬁcant decrease in GSH content. After 4 days exposure to 5M
Menadione, GSH content had declined to 2.97±0.20nmol/well
compared with controls (3.73±0.03nmol/well). The correspond-
ing value after 0.01mM H2O2 exposure was 3.40±0.21nmol/well
in comparison with controls (4.22±0.18nmol/well) (P<0.05). Cell
death was not observed until 9 days exposure to the toxins when
CVstainingwas signiﬁcantlydecreased (P<0.05). IGFBP-5 secretion
into the medium was lower in samples from cells following expo-
sure to toxins than in the control samples taken at the same time
points (Fig. 1). It should be noted that IGFBP-5 secretion increased
in the control samples between 3 and 9 days in culture (P<0.05).
These results suggest that IGFBP-5secretionmaybeassociatedwith
de-differentiation, andhave a role in the decline of cellular function
in hepatocytes during culture, but does not appear to be involved in
toxicity by oxidative stress as induced byMenadione and hydrogen
peroxide.
Acknowledgement: EML is an EPSRC funded student.
References
Blechacz, B., Gores, G.J., 2008. J. Hepatol. 49, 160–162.
Yasuoka, H., Jukic, D.M., Zhou, Z., Choi, A.M.K., Feghali-Bostwick, C.A., 2006a. Arthrit.
Rheum. 54, 3001–3010.
Yasouka, H., Zhou, Z., Pilewski, J.M., Oury, T.D., Choi, A.M.K., Feghali-Bostwick, C.A.,
2006b. Am. J. Pathol. 169, 1633–1642.
doi:10.1016/j.tox.2010.08.107
P28
Protein binding and pharmacokinetics of reactive acyl glu-
curonide drug metabolites
Thomas G. Hammond1,∗, Sophie L. Regan1,∗, Xiaoli Meng1, James
L. Maggs1, Rosalind E. Jenkins1, Gerry L. Kenna2, Jean G. Sathish1,
Dominic P. Williams1, B. Kevin Park1
1 MRC Centre for Drug Safety Science, Department Pharmacology and
Therapeutics, Sherrington Building, Ashton Street, The University of
Liverpool, Liverpool, L693GE, UK
2 Molecular Toxicology, Safety Assessment UK, 23S69 Mereside, Alder-
ley Park, Macclesﬁeld, Cheshire, SK10 4TG, UK
E-mail address: Thomas.hammond@liverpool.ac.uk (T.G. Ham-
mond).
Tolmetin and diclofenac are members of the non-steroidal anti-
inﬂammatory class of drugs (NSAIDs). Many NSAIDs have been
associated with idiosyncratic toxicity, manifesting in hepatotox-
icity or hypersensitivity reactions. These adverse reactions have
been suggested to be a result of bioactivation to protein reac-
tive metabolites. It is hypothesised that acyl glucuronide (AG)
metabolites are sufﬁciently protein reactive to elicit an idiosyn-
cratic reaction through the initiation of an immune response
(Bailey and Dickenson, 2003). We have investigated this possi-
bility through the incubation of the synthetic AG metabolites of
diclofenac and tolmetin with human, rat and mouse serum albu-
min. We have investigated the metabolism of two NSAIDs into
their AG metabolites, their AG-mediated protein binding, and are
currently investigating rates of AG clearance in the rat.
Tolmetin acyl glucuronide (T-AG) and diclofenac acyl glu-
curonide (D-AG)were incubatedwithhuman serumalbumin (HSA)
at increasing concentrations for 16h at 37 ◦C, with AG covalent
adduct formation assessed using LC–MS/MS technology (AB Sciex
QTRAP 5500.)
Male Wistar rats were anaesthetized using 14% urethane, with
the bile duct and carotid artery cannulated. Tolmetin was then
administered orally at a dose of 10mg/kg, with bile and blood
samples collected over 4h for pharmacokinetic analysis (n=3).
Following anesthesia, the femoral vein of male Wistar rats were
cannulated with D-AG administered through this route at a dose
of 60mg/kg. Blood samples were collected, and albumin was iso-
lated using preparative HPLC. Adducts were searched for using an
AB Sciex QTRAP 5500 LC–MS/MS (Table 1).
Following in vitro incubation of T-AG with rat (RSA) and mouse
(MSA) serum albumin, following the same procedure as for HSA,
fewer amino acids were found to be modiﬁed at higher concen-
trations and adducts were not found at lower concentrations of
1:1 molar ratios, unlike following incubation with HSA. No albu-
min adducts were detected following i.v. administration of D-AG at
